Neurotrophic Keratitis Treatment Global Market Report 2024

Description

“Neurotrophic Keratitis Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurotrophic keratitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurotrophic keratitis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The neurotrophic keratitis treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
2) By Route of Administration: Oral; Topical; Other Routes of Administration
3) By Application: Stage I; Stage II; Stage III
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Companies Mentioned: Eyevance Pharmaceuticals LLC; Grand Pharma Co. Ltd.; Walgreen Co.; Pfizer Inc.; Johnson and Johnson
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Neurotrophic keratitis treatment is a method aimed at addressing a rare eye condition resulting from damage to the trigeminal nerve, leading to reduced corneal sensation and potential corneal harm. The objective of this treatment is to safeguard the cornea, facilitate recovery, alleviate symptoms, and prevent further damage. aimed at addressing a rare.

The main approaches of neurotrophic keratitis treatment are employed in neurotrophic keratitis treatment, including topical antibiotics, recombinant human nerve growth factor (rhNGF), amniotic membrane transplantation, keratoplasty, among others. Topical antibiotics are antimicrobial drugs administered directly to the skin or mucous membranes. They can be administered through various routes, such as oral, topical, and others, catering to stages I, II, and III of neurotropic keratitis. These treatments are utilized by different end-users, including hospitals, homecare, specialty clinics, among others.

The neurotrophic keratitis treatment market research report is one of a series of new reports from The Business Research Company that provides neurotrophic keratitis treatment market statistics, including neurotrophic keratitis treatment industry global market size, regional shares, competitors with a neurotrophic keratitis treatment market share, detailed neurotrophic keratitis treatment market segments, market trends and opportunities and any further data you may need to thrive in the neurotrophic keratitis treatment industry. This neurotrophic keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurotrophic keratitis treatment market size has grown strongly in recent years. It will grow from $4.7 billion in 2023 to $5.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased diagnoses, increasing injury and surgical procedures, rising research and development, global healthcare infrastructure.

The neurotrophic keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to educational initiatives, increasing clinical trials, advanced therapies, regulatory approvals. Major trends in the forecast period include improved diagnostic tools, digital health solutions, neuroprotection strategies, advanced ocular surface imaging.

The escalating incidence of eye conditions is anticipated to drive the expansion of the neurotrophic keratitis treatment market in the foreseeable future. Eye conditions encompass a wide spectrum of medical issues and disorders affecting the structure and functionality of the eyes. Neurotrophic keratitis treatment plays a crucial role in enhancing corneal sensation, fostering healing, averting infections, and alleviating pain and discomfort. For example, in March 2022, as reported by Eye Care One, a US-based platform for eyecare career development services, an estimated 35 million individuals in the United States were projected to experience dry eye disease (DED) in 2022, with prevalence expected to increase annually. Additionally, in March 2021, as per data from the Eyes of the World Foundation, a non-profit organization based in Spain, it was predicted that there would be 1.1 billion people experiencing vision loss in 2021, a number projected to rise to 1.7 billion by 2050. Hence, the mounting incidence of eye conditions is steering the growth of the neurotrophic keratitis treatment market.

The surge in healthcare investments, particularly in the domain of eye care, is anticipated to be a driving force behind the expansion of the neurotrophic keratitis treatment market in the foreseeable future. These investments involve directing financial resources towards bolstering the development, enhancement, and availability of medical services and treatments, with a special emphasis on addressing vision-related health requirements. Such investments hold significant potential in propelling the advancement of neurotrophic keratitis treatment. They have the capacity to pave the way for groundbreaking therapies and the development of pharmaceuticals, ultimately leading to improved outcomes for patients and an elevated quality of life for those grappling with this condition. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a prominent U.S. national public health agency, reported that their budget request for FY 2023 to Congress encompassed a comprehensive funding package of $10.675 billion. This funding was allocated across discretionary budget authority, Public Health Service (PHS) Evaluation Funds, and the Prevention and Public Health Fund (PPHF). Notably, the CDC's FY 2023 President's Budget specifically earmarked $1,000, while the operating plan allotted $2,500 towards vision and eye health initiatives. This substantial financial commitment underscores the escalating investments in healthcare, particularly in the realm of eye care, and is a driving force behind the expansion of the neurotrophic keratitis treatment market.

Rising treatment expenses are anticipated to impede the neurotrophic keratitis treatment market in the future. The costs associated with treating neurotrophic keratitis (NK) have risen, largely attributed to the introduction of advanced therapies like Cenegermin (Oxervate), a medication containing recombinant human nerve growth factor (rhNGF). For instance, in March 2022, the National Center for Biotechnology Information (NCBI), a US-based organization specializing in biomedical research and information, reported that in Germany, the total cost of an eight-week course of Cenegermin 20 mg/ml therapy is approximately $21.20 USD (20.000 EURO). This is nearly 25 times pricier than a 16-week supply of autologous serum eye drops, six times more costly than amniotic membrane transplantation (AMT), and three times the expense of penetrating keratoplasty (PK) in Germany. As a result, the escalating treatment expenses are acting as a constraint on the neurotrophic keratitis treatment market.

Prominent companies in the neurotrophic keratitis treatment market are actively engaged in the development and approval of innovative drugs to fortify their market presence. Drug development holds significant importance in the treatment of neurotrophic keratitis, given the existing limitations in available treatments and the pressing need for more effective solutions to halt the disease's progression. A case in point is BRIM Biotechnology Inc., a clinical-stage company based in Taiwan, which secured Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for BRM424, a recombinant human nerve growth factor. This compound stimulates the proliferation and differentiation of corneal limbal stem cells, facilitating the regeneration and restoration of corneal health in patients afflicted with neurotrophic keratitis.

In July 2022, Regenerx Biopharmaceuticals Inc., a US-based clinical-stage drug development company, along with its joint venture and licensee partner, HLB Therapeutics Co. Ltd., a biotechnology company based in South Korea, entered into a letter of intent with a global ophthalmology contract research organization (CRO). This collaboration is focused on conducting Phase III clinical trials in the US and Europe for the treatment of neurotrophic keratitis (NK). RGN-259, a sterile and preservative-free eye drop formulation containing thymosin beta 4, a naturally occurring peptide that facilitates tissue repair and healing, is the subject of evaluation. The Phase III clinical trial will assess the efficacy and safety of RGN-259 ophthalmic solution in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathies.clinical-stage drug development company.

Major players in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited .

North America was the largest region in the neurotrophic keratitis treatment market in 2023. The regions covered in neurotrophic keratitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurotrophic keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurotrophic keratitis treatment market consists of revenues earned by entities by providing services such as ophthalmic evaluation, prescription of medications, corneal neurotization, customized treatment plans, counseling and support, tarsorrhaphy and antibiotic medication supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurotrophic keratitis market also includes sales of artificial tears, recombinant human nerve growth factor eye drops, antibiotics and bandage contact lenses. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12314

1. Executive Summary

2. Neurotrophic Keratitis Treatment Market Characteristics

3. Neurotrophic Keratitis Treatment Market Trends And Strategies

4. Neurotrophic Keratitis Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Neurotrophic Keratitis Treatment Market Size and Growth

5.1. Global Neurotrophic Keratitis Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Neurotrophic Keratitis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Neurotrophic Keratitis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neurotrophic Keratitis Treatment Market Segmentation

6.1. Global Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Topical Antibiotics
Recombinant Human Nerve Growth Factor (rhNGF)
Amniotic Membrane Transplantation
Keratoplasty
Other Treatments
6.2. Global Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Topical
Other Routes of Administration
6.3. Global Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Stage I
Stage II
Stage III
6.4. Global Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users

7. Neurotrophic Keratitis Treatment Market Regional And Country Analysis

7.1. Global Neurotrophic Keratitis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Neurotrophic Keratitis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neurotrophic Keratitis Treatment Market

8.1. Asia-Pacific Neurotrophic Keratitis Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neurotrophic Keratitis Treatment Market

9.1. China Neurotrophic Keratitis Treatment Market Overview
9.2. China Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neurotrophic Keratitis Treatment Market

10.1. India Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neurotrophic Keratitis Treatment Market

11.1. Japan Neurotrophic Keratitis Treatment Market Overview
11.2. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neurotrophic Keratitis Treatment Market

12.1. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neurotrophic Keratitis Treatment Market

13.1. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neurotrophic Keratitis Treatment Market

14.1. South Korea Neurotrophic Keratitis Treatment Market Overview
14.2. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neurotrophic Keratitis Treatment Market

15.1. Western Europe Neurotrophic Keratitis Treatment Market Overview
15.2. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neurotrophic Keratitis Treatment Market

16.1. UK Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neurotrophic Keratitis Treatment Market

17.1. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neurotrophic Keratitis Treatment Market

18.1. France Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neurotrophic Keratitis Treatment Market

19.1. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neurotrophic Keratitis Treatment Market

20.1. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neurotrophic Keratitis Treatment Market

21.1. Eastern Europe Neurotrophic Keratitis Treatment Market Overview
21.2. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neurotrophic Keratitis Treatment Market

22.1. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neurotrophic Keratitis Treatment Market

23.1. North America Neurotrophic Keratitis Treatment Market Overview
23.2. North America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neurotrophic Keratitis Treatment Market

24.1. USA Neurotrophic Keratitis Treatment Market Overview
24.2. USA Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neurotrophic Keratitis Treatment Market

25.1. Canada Neurotrophic Keratitis Treatment Market Overview
25.2. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neurotrophic Keratitis Treatment Market

26.1. South America Neurotrophic Keratitis Treatment Market Overview
26.2. South America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neurotrophic Keratitis Treatment Market

27.1. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neurotrophic Keratitis Treatment Market

28.1. Middle East Neurotrophic Keratitis Treatment Market Overview
28.2. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neurotrophic Keratitis Treatment Market

29.1. Africa Neurotrophic Keratitis Treatment Market Overview
29.2. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Neurotrophic Keratitis Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Neurotrophic Keratitis Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neurotrophic Keratitis Treatment Market Competitive Landscape And Company Profiles

30.1. Neurotrophic Keratitis Treatment Market Competitive Landscape
30.2. Neurotrophic Keratitis Treatment Market Company Profiles
- 30.2.1. Eyevance Pharmaceuticals LLC
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Grand Pharma Co. Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Walgreen Co.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Pfizer Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Johnson and Johnson
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Neurotrophic Keratitis Treatment Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Novartis AG
31.3. Abbott Laboratories
31.4. Gilead Biosciences Inc.
31.5. Merck and Co. Inc.
31.6. Allergan Inc.
31.7. Alcon Inc.
31.8. Bausch Health Companies Inc.
31.9. Bausch & Lomb Inc.
31.10. CooperVision Inc.
31.11. Rohto Pharmaceutical Co. Ltd.
31.12. Santen Pharmaceutical Co. Ltd.
31.13. Zhejiang Conba Pharmaceutical Co. Ltd.
31.14. Glenmark Pharmaceuticals Limited
31.15. Dompe farmaceutici S.p.A

32. Global Neurotrophic Keratitis Treatment Market Competitive Benchmarking

33. Global Neurotrophic Keratitis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neurotrophic Keratitis Treatment Market

35. Neurotrophic Keratitis Treatment Market Future Outlook and Potential Analysis

35.1 Neurotrophic Keratitis Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Neurotrophic Keratitis Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Neurotrophic Keratitis Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer